Pharmaceutical Industry in Asia Countries: Market Research Reports, Statistics and Analysis

The Indian Pharmaceutical Industry Analysis

... Early detection of hiv Provision of basic information on modes of transmission and prevention of hiv/aids so as to promote behavioral change and reduce vulnerability (both for hiv positive ...

Company Report: Pathology In China For Year 2013

... English translation being screening method for upper respiratory tract infections pharmaceutical preparation) treatment for acute and chronic upper respiratory tract infections, constipation ...

The Singaporean Vaccine Market : Innovation And Technology Trends

... Manufacturing innovative approaches to expand influenza vaccine production capabilities alliances and partnerships in driving vaccine development in asia evaluating novel adjuvant ...

Company Report: Generic Drug In India, Japan And The United State ...

... For developing and manufacturing generic drugs in japan. However, as fujifilm realigns its long-term growth strategy for the pharmaceutical business, both companies have led to a mutual agreement to terminate ...

Company Report: Pathology In Japan For Year 2013

... Ab antibody oncolytic vaccine protein/peptibody small molecule gastric cancerrilotumumab (amg 102) gastric cancer: both sexes, all ages Human monoclonal antibody Anti-hgf mab m t lit china japan 102,040 464 ...

Company Report: Anti-infective In India For Year 2013

... Company drug name therapeutic area innovator company generic version of market size aurobindo pharma cefadroxil/cefadroxil hemihydrate tablets anti-infective warner chilcott duricef na aurobindo pharma ...

The Indian Drug And Medication Industry : Innovation And Technolo ...

Mediaid Inc. - Company Report For Year 2013

... tramadol hydrochloride pain management tramadol grunethal gmbh na cadila healthcare clopidogrel bisulfate anti-coagulant bms \ sanofi aventis plavix us$ 6 billion cadila healthcare donepezil hydrochloride ...

Pharmaceutical Business Analysis In The United States And Qatar

... There is strong and powerful evidence for the clinical and cost effectiveness of increasing all use in cad and diabetes (55+) populations Significant reductions in future cardiovascular disease in patients ...